Oligodendroglioma: A Review of Management and Pathways
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Frontiers Media S.A.
Abstract
Anaplastic oligodendrogliomas are a type of glioma that occurs primarily in adults but are also found in children. These tumors are genetically defined according to the mutations they harbor. Grade II and grade III tumors can be differentiated most of the times by the presence of anaplastic features. The earliest regimen used for the treatment of these tumors was procarbazine, lomustine, and vincristine. The treatment modalities have shifted over time, and recent studies are considering immunotherapy as an option as well. This review assesses the latest management modalities along with the pathways involved in the pathogenesis of this malignancies. © Copyright © 2021 Bou Zerdan and Assi.
Description
Keywords
Anaplastic oligodendroglioma, Idh mutation, Lomustine, Pcv, Procarbazine, Temozolomide, Vincristine, Cyclin dependent kinase inhibitor 2a, Isocitrate dehydrogenase 1, Isocitrate dehydrogenase 2, Notch1 receptor, Platelet derived growth factor, Telomerase reverse transcriptase, Cancer chemotherapy, Cancer grading, Cancer growth, Cancer immunotherapy, Carcinogenesis, Chromosome 1p, Chromosome 9p, Chromosome deletion, Cic gene, Fubp1 gene, Gene, Gene mutation, Glioma, Human, Oligodendroglioma, Phase 1 clinical trial (topic), Phase 2 clinical trial (topic), Phase 3 clinical trial (topic), Phase 4 clinical trial (topic), Protein expression, Randomized controlled trial (topic), Review, Signal transduction